# A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India

> **NCT07685769** · PHASE4 · RECRUITING · sponsor: **Pfizer** · enrollment: 60 (estimated)

## Conditions studied

- Acute Treatment of Migraine

## Interventions

- **DRUG:** Rimegepant 75 mg ODT

## Key facts

- **NCT ID:** NCT07685769
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-24
- **Primary completion:** 2028-01-04
- **Final completion:** 2028-01-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685769, "A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*